The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Perturbations of the AKT signaling pathway in human cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
Anoikis molecular pathways and its role in cancer progression
Paoli, P., Giannoni, E., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.026 · Cited by 1,160
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Hemmings, B. A., & Restuccia, D. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011189 · Cited by 1,049
AKT as a Therapeutic Target for Cancer
Song, M., Bode, A. M., Dong, Z., & Lee, M.-H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2738 · Cited by 782
Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation
Wang, R. C., Wei, Y., An, Z., Zou, Z., Xiao, G., Bhagat, G., White, M., Reichelt, J., & Levine, B. (2012) · Science · doi:10.1126/science.1225967 · Cited by 728
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Akt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
The relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Cheng, G. Z., Chan, J., Wang, Q., Zhang, W., Sun, C. D., & Wang, L.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1479 · Cited by 546
Signalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Long, H.-Z., Cheng, Y., Zhou, Z.-W., Luo, H.-Y., Wen, D.-D., & Gao, L.-C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648636 · Cited by 489
The Akt kinases: Isoform specificity in metabolism and cancer
Gonzalez, E., & McGraw, T. E. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9335 · Cited by 472
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 471
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Incio, J., Liu, H., Suboj, P., Chin, S. M., Chen, I. X., Pinter, M., Ng, M. R., Nia, H. T., Grahovac, J., Kao, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1177 · Cited by 456
Song, L.-B., Li, J., Liao, W.-T., Feng, Y., Yu, C.-P., Hu, L.-J., Kong, Q.-L., Xu, L.-H., Zhang, X., Liu, W.-L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39374 · Cited by 398
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R., Mouret-Reynier, M.-A., Kalev, D., Egle, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 381
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Degtyarev, M., De Mazière, A., Orr, C., Lin, J., Lee, B. B., Tien, J. Y., Prior, W. W., van Dijk, S., Wu, H., Gray, D. C., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801099 · Cited by 366
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B. M., et al. (2014) · Nature · doi:10.1038/nature13079 · Cited by 361
The Akt–SREBP nexus: cell signaling meets lipid metabolism
Krycer, J. R., Sharpe, L. J., Luu, W., & Brown, A. J. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.001 · Cited by 360
Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway
Shiojima, I., & Walsh, K. (2006) · Genes & Development · doi:10.1101/gad.1492806 · Cited by 356
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 355
Pappa, K. I., Polyzos, A., Jacob-Hirsch, J., Amariglio, N., Vlachos, G. D., Loutradis, D., & Anagnou, N. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142229 · Cited by 354
The role of phosphatidylcholine and choline metabolites to cell proliferation and survival
Ridgway, N. D. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.735643 · Cited by 339
FoxO Transcription Factors and Stem Cell Homeostasis: Insights from the Hematopoietic System
Tothova, Z., & Gilliland, D. G. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.017 · Cited by 331
Adipose tissue, obesity and adipokines: role in cancer promotion
Booth, A., Magnuson, A., Fouts, J., & Foster, M. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0037 · Cited by 329
The Akt pathway in oncology therapy and beyond (Review)
Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 328
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Gills, J. J., LoPiccolo, J., Tsurutani, J., Shoemaker, R. H., Best, C. J. M., Abu-Asab, M. S., Borojerdi, J., Warfel, N. A., Gardner, E. R., Danish, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0161 · Cited by 320
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Julien, S. G., Dubé, N., Read, M., Penney, J., Paquet, M., Han, Y., Kennedy, B. P., Muller, W. J., & Tremblay, M. L. (2007) · Nature Genetics · doi:10.1038/ng1963 · Cited by 316
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Astle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., & Pearson, R. B. (2012) · Oncogene · doi:10.1038/onc.2011.394 · Cited by 295
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
Akt Signaling and Cancer: Surviving but not Moving On
Toker, A., & Yoeli-Lerner, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0743 · Cited by 295
MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia
Yu, J., Ryan, D. G., Getsios, S., Oliveira-Fernandes, M., Fatima, A., & Lavker, R. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803992105 · Cited by 276
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
MicroRNA-301 Mediates Proliferation and Invasion in Human Breast Cancer
Shi, W., Gerster, K., Alajez, N. M., Tsang, J., Waldron, L., Pintilie, M., Hui, A. B., Sykes, J., P'ng, C., Miller, N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3369 · Cited by 266
MicroRNA and cancer: Current status and prospective
Wu, W., Sun, M., Zou, G., & Chen, J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22454 · Cited by 266
Lin, A., Hu, Q., Li, C., Xing, Z., Ma, G., Wang, C., Li, J., Ye, Y., Yao, J., Liang, K., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3473 · Cited by 263
AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias
Sykes, S. M., Lane, S. W., Bullinger, L., Kalaitzidis, D., Yusuf, R., Saez, B., Ferraro, F., Mercier, F., Singh, H., Brumme, K. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.032 · Cited by 257
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer
Chin, Y. R., & Toker, A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.015 · Cited by 255
Karimi Roshan, M., Soltani, A., Soleimani, A., Rezaie Kahkhaie, K., Afshari, A. R., & Soukhtanloo, M. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.003 · Cited by 254
DeBerardinis, R. J., Lum, J. J., & Thompson, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608372200 · Cited by 221
Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein
Menges, C. W., Baglia, L. A., Lapoint, R., & McCance, D. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0499 · Cited by 145
Lee, W. H., Choong, L. Y., Jin, T. H., Mon, N. N., Chong, S., Liew, C. S., Putti, T., Lu, S. Y., Harteneck, C., & Lim, Y. P. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.39 · Cited by 121
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
“Under physiological conditions, activation of the anabolic PI3K/ Akt/mTOR pathway results in down-regulation of MuRF1 and MAfxb through inhibition of FoxO [12, 119, 136] and simultaneous stimulation of protein synthesis by activation of mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3β (GSK3β) [12,…”
BackgroundLi, J., Lai, Y., Cao, Y., Du, T., Zeng, L., Wang, G., Chen, X., Chen, J., Yu, Y., Zhang, S., et al. (2015) · Medical Oncology · doi:10.1007/s12032-014-0444-3 · Cited by 91
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress
Mehra, S., Deshpande, N., & Nagathihalli, N. (2021) · Cancers · doi:10.3390/cancers13174434 · Cited by 85
Yuan, Z., Kim, D., Shu, S., Wu, J., Guo, J., Xiao, L., Kaneko, S., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059675 · Cited by 78
RetractedMartínez-Cruz, A. B., Santos, M., Lara, M. F., Segrelles, C., Ruiz, S., Moral, M., Lorz, C., García-Escudero, R., & Paramio, J. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3049 · Cited by 65
Ye, Y., Xiao, L., Wang, S.-J., Yue, W., Yin, Q.-S., Sun, M.-Y., Xia, W., Shao, Z.-Y., & Zhang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.6473 · Cited by 47
Zhang, C., Zhang, C.-D., Ma, M.-H., & Dai, D.-Q. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i11.1206 · Cited by 40
Jiang, S.-L., Guan, Y.-D., Chen, X.-S., Ge, P., Wang, X.-L., Lao, Y.-Z., Xiao, S.-S., Zhang, Y., Yang, J.-M., Xu, X.-J., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0165-9 · Cited by 37
Padala, R. R., Karnawat, R., Viswanathan, S. B., Thakkar, A. V., & Das, A. B. (2017) · Molecular BioSystems · doi:10.1039/c6mb00786d · Cited by 33
Computed cancer interactome explains the effects of somatic mutations in cancers
Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31
SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway
Liu, Z., Wang, Q., Zhai, G., Ke, S., Yu, X., & Guo, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02546-6 · Cited by 22
Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas
Takahashi, Y., Kohashi, K., Yamada, Y., Endo, M., Setsu, N., Ishii, T., Yamamoto, H., Iwamoto, Y., & Oda, Y. (2014) · Human Pathology · doi:10.1016/j.humpath.2013.12.012 · Cited by 11
(2010) · PubMed Central
Metadata
- Authors
- Altomare, D. A., & Testa, J. R.
- Venue
- Oncogene
- Published
- 2005-11-14
- Volume
- 24
- Issue
- 50
- Pages
- 7455-7464
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1966133006
- Cited by
- 1,329
- References
- 88
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.